Hepatocyte Growth Factor Articles & Analysis
5 news found
Creative Diagnostics, a global leader in offering raw materials, antibodies, and reagents for the biotechnology industry, expanded its monoclonal antibodies capabilities and offerings to global customers, including over 1,000 of targets, carrier-free formulations, and conjugated antibodies. Monoclonal antibodies (mAbs) are generated by identical B cells that are cloned from a single parent cell. ...
It is also a good thing for Vilixen that Enzion Biomedica, which was targeting this market by using hepatocyte growth factor receptor (c-MET), failed to prove efficacy in phase 3 clinical trials at the end of last year. ...
Ficlatuzumab is AVEO’s investigational potent humanized immunoglobulin G1 monoclonal antibody that targets hepatocyte growth factor. “This collaboration with Merck KGaA, Darmstadt, Germany will play an important role in the advancement of both the ficlatuzumab and cetuximab programs,” said Michael Bailey, president and chief ...
” It is also a good thing that Nzion Biomedica, the U.S., which used hepatocyte growth factor receptor (c-MET) to target this market, failed to prove efficacy in phase 3 clinical trials at the end of last year. ...
Fibralign announced today that it has been awarded a Small Business Innovation Research (SBIR) Sequential Phase II (Phase IIS) from the Department of Defense (DoD) Defense Health Program (DHP). This two-year grant provides $996,609 in funding to continue advancing Fibralign’s development of a novel treatment of volumetric muscle loss. Project Title: Aligned ...